公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2001 | Methylation of the p15INK4B gene in myelodysplastic syndrome: It can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation | HWEI-FANG TIEN ; JIH-LUH TANG ; WOEI TSAY ; Liu M.-C.; Lee F.-Y.; Wang C.-H.; YAO-CHANG CHEN ; MING-CHING SHEN | British Journal of Haematology | 152 | 128 | |
2011 | Poems syndrome with calciphylaxis: A case report | Lee F.-Y.; HSIEN-CHING CHIU | Acta Dermato-Venereologica | 23 | 21 | |
2005 | A potential role of YC-I on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models | Pan S.-L.; JIH-HWA GUH ; Peng C.-Y.; Chang Y.-L.; Cheng F.-C.; Chang J.-H.; Kuo S.-C.; Lee F.-Y.; Teng C.-H. | Thrombosis and Haemostasis | 32 | 31 | |
2011 | The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia | WEN-CHIEN CHOU ; Lei W.-C.; BOR-SHENG KO ; HSIN-AN HOU ; Chen C.-Y.; JIH-LUH TANG ; MING YAO ; WOEI TSAY ; SHANG-JU WU ; SHANG-YI HUANG ; SZU-CHUN HSU ; YAO-CHANG CHEN ; Chang Y.-C.; KUAN-TING KUO ; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tseng M.-H.; Huang C.-F.; HWEI-FANG TIEN | Leukemia | 132 | 132 | |
2014 | SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution | CHIEN-CHIN LIN ; HSIN-AN HOU ; WEN-CHIEN CHOU ; Kuo Y.-Y.; SHANG-JU WU ; Liu C.-Y.; Chen, Chien-Yuan ; Tseng M.-H.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; JIH-LUH TANG ; MING YAO ; SHANG-YI HUANG ; SZU-CHUN HSU ; BOR-SHENG KO ; WOEI TSAY ; YAO-CHANG CHEN ; HWEI-FANG TIEN | American Journal of Hematology | 30 | 26 | |
2012 | A solitary papule on the scalp | Lee F.-Y.; WEI-HSIN WU ; Hsiao C.-H. | Dermatologica Sinica | 0 | 0 | |
2011 | TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics | WEN-CHIEN CHOU ; SHENG-CHIEH CHOU ; Liu C.-Y.; Chen, Chien-Yuan ; HSIN-AN HOU ; Kuo Y.-Y.; Lee M.-C.; BOR-SHENG KO ; JIH-LUH TANG ; MING YAO ; WOEI TSAY ; SHANG-JU WU ; SHANG-YI HUANG ; SZU-CHUN HSU ; YAO-CHANG CHEN ; Chang Y.-C.; Kuo Y.-Y.; KUAN-TING KUO ; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tseng M.-H.; Huang C.-F.; HWEI-FANG TIEN | Blood | 255 | 235 | |
2011 | Treatment of acquired reactive perforating collagenosis with allopurinol incidentally improves scleredema diabeticorum | Lee F.-Y.; HSIEN-YI CHIU ; HSIEN-CHING CHIU | Journal of the American Academy of Dermatology | 17 | 0 | |
2010 | WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system | HSIN-AN HOU ; TAI-CHUNG HUANG ; LIANG-IN LIN ; Liu C.-Y.; Chen, Chien-Yuan ; WEN-CHIEN CHOU ; JIH-LUH TANG ; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Lee F.-Y.; Liu M.-C.; MING YAO ; SHANG-YI HUANG ; BOR-SHENG KO ; SZU-CHUN HSU ; SHANG-JU WU ; WOEI TSAY ; YAO-CHANG CHEN ; HWEI-FANG TIEN | Blood | 142 | 137 | |
2005 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G 0-G1 in human hepatocellular carcinoma cells | Wang S.-W.; Pan S.-L.; JIH-HWA GUH ; Chen H.-L.; Huang D.-M.; Chang Y.-L.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 47 | 47 | |
2005 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models | Pan S.-L.; JIH-HWA GUH ; Peng C.-Y.; Wang S.-W.; Chang Y.-L.; Cheng F.-C.; Chang J.-H.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 55 | 53 | |
2006 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9 | Liu Y.-N.; Pan S.-L.; Peng C.-Y.; JIH-HWA GUH ; Huang D.-M.; Chang Y.-L.; Lin C.-H.; Pai H.-C.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 39 | 33 | |
2007 | YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-κB in microglia | Lu D.-Y.; Tang C.-H.; Liou H.-C.; Teng C.-M.; Jeng K.-C.G.; Kuo S.-C.; Lee F.-Y.; WEN-MEI FU | British Journal of Pharmacology | 57 | 55 | |
2008 | YC-1 induces heat shock protein 70 expression and prevents oxidized LDL-mediated apoptosis in vascular smooth muscle cells | Liu Y.-N.; Pan S.-L.; Peng C.-Y.; Huang D.-Y.; JIH-HWA GUH ; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Shock | 12 | 10 | |
2007 | YC-1 inhibits HIF-1 expression in prostate cancer cells: Contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia | Sun H.-L.; Liu Y.-N.; Huang Y.-T.; Pan S.-L.; Huang D.-Y.; JIH-HWA GUH ; Lee F.-Y.; Kuo S.-C.; Teng C.-M. | Oncogene | 161 | 158 | |
2005 | YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells | Huang Y.-T.; Pan S.-L.; JIH-HWA GUH ; Chang Y.-L.; Lee F.-Y.; Kuo S.-C.; Teng C.-M. | Molecular Cancer Therapeutics | 45 | 43 |